Atossa Genetics launches breast cancer products in Europe

• Nano cap Atossa Genetics (NASDAQ:ATOS) is up 17% premarket on robust volume on its announcement that the commercial launch of its ForeCYTE Breast Aspirator and Collection Kit within the European Union in underway. The initial efforts will be in The Netherlands, Germany, Switzerland and the U.K.
• The company has been busy positioning itself to hit its 2015 revenue goal of $8M. It recently signed distribution deals with Henry Schein and Thermo Fisher.
• Previously: Atossa adds to distribution deal-stoked up move (Feb. 13)
• Previously: Atossa up premarket on deal with leading medical products distributor (Feb. 26)